Cardiovascular Complications in Patients with Klinefelter's Syndrome.
Klinefelter syndrome
cardiac abnormalities
cardiovascular diseases
cardiovascular risk
hypogonadism
metabolic syndrome
thromboembolic disease
Journal
Current pharmaceutical design
ISSN: 1873-4286
Titre abrégé: Curr Pharm Des
Pays: United Arab Emirates
ID NLM: 9602487
Informations de publication
Date de publication:
2020
2020
Historique:
received:
26
03
2020
accepted:
01
10
2020
pubmed:
4
11
2020
medline:
27
4
2021
entrez:
3
11
2020
Statut:
ppublish
Résumé
More than 70 years have passed since the first description of Klinefelter Syndrome (KS), the most frequent chromosome disorder causing male infertility and hypogonadism. KS is associated with increased cardiovascular (CV) mortality due to several comorbidities, including hypogonadism, as well as metabolic syndrome and type 2 diabetes, which are highly prevalent in these patients. Aside from metabolic disturbances, patients with KS suffer from both acquired and congenital CV abnormalities, cerebrovascular thromboembolic disease, subclinical atherosclerosis and endothelial dysfunction, which may all contribute to increased CV mortality. The mechanisms involved in this increased risk of CV morbidity and mortality are not entirely understood. More research is needed to better characterise the CV manifestations, elucidate the pathophysiological mechanisms and define the contribution of testosterone replacement to restoring CV health in KS patients. This review explores the complex association between KS, metabolic syndrome and CV risk in order to plan future studies and improve strategies to reduce mortality in this high-risk population.
Identifiants
pubmed: 33138758
pii: CPD-EPUB-111072
doi: 10.2174/1381612826666201102105408
doi:
Substances chimiques
Testosterone
3XMK78S47O
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
5556-5563Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.